Coherus BioSciences Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Total Funding:$327.5M
Industry:Biotech
Founded:2010
Lead Investor(s):Healthcare Royalty Partners
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Coherus BioSciences's estimated annual revenue is currently $22.8M per year.
  • Coherus BioSciences received $75.0M in venture funding in January 2019.
  • Coherus BioSciences's estimated revenue per employee is $81,960
  • Coherus BioSciences's total funding is $327.5M.

Employee Data

  • Coherus BioSciences has 278 Employees.
  • Coherus BioSciences grew their employee count by 15% last year.
  • Coherus BioSciences currently has 22 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.7M4310%N/A
Mission Bio
$11.5M7445%N/A
Geron Corporati...
N/A197N/AN/A
Rigel Pharmaceu...
$45M2904%N/A
Althea Technolo...
$21.4M138N/AN/A
INOVA Diagnosti...
$37.5M242N/AN/A
ProTrials Resea...
$28.2M1823%N/A
Trace Genomics
$6.4M4137%N/A
Advanced Cell D...
$27.6M1788%N/A
The J. Craig Ve...
$33.3M215N/AN/A
Missing a competitor? Contribute!?
Submit

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

278

Number of Employees

$22.8M

Revenue (est)

22

Current Jobs

15%

Employee Growth %

$327.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Alan HermanGeneral ManagerEmail Available
Francesca CivoliDirector, Preclinical DevelopmentEmail Available
Lee MermelsteinSenior Vice President Manufacturing
Erik WibergExecutive Vice President, Corporate DevelopmentEmail Available
Juliana ReedVice President, Government AffairsEmail Available
Richard BoismenuVice President Of Product DevelopmentEmail Available
Joan EggertSenior Vice President, Transactions & Legal AffairsEmail Available
Sarita JainVice President, Business DevelopmentEmail Available
Francie LinSr Director, Commercial AnalyticsEmail Available
Jun LiuVice President OperationsEmail Available

Coherus BioSciences News

09/03/2019 - Coherus BioSciences Announces New Employment ...

REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective ...

09/08/2019 - Coherus Biosciences (NASDAQ:CHRS) Downgraded by ...

BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a report released on Friday, BidAskClub ...

09/03/2019 - Coherus BioSciences, Inc. (CHRS) Fell By -2.8%, And Here's ...

For its latest trading sesion, Coherus BioSciences, Inc. (CHRS) dropped by -2.8% – here is what that looked like (as of 2019-09-09): ...

Coherus BioSciences Funding

DateAmountRoundLead InvestorsReference
2014-05-20$55.0MCMultipleArticle
2014-11-07$85.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-03-31$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-02$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-02-09$143.8MUndisclosedJ.P. MorganArticle
2019-01-08$75.0MUndisclosedHealthcare Royalty PartnersArticle

Coherus BioSciences Executive Hires

DateNameTitleReference
2014-04-29Michael A. FlemingSVP Commercial StrategyArticle
2014-05-13Lisa M. BellSVP Global Regulatory AffairsArticle
2014-06-10Vince R. AnicettiSVP Global QualityArticle
2016-05-17Patrick O?BrienSVP Investor RelationsArticle
2017-03-28Erik Wibergvp Corporate DevelopmentArticle
2019-01-03Darlene HortonChief Medical and Regulatory Affairs OfficerArticle
2019-03-19Thomas FitzpatrickChief Legal OfficerArticle

Coherus BioSciences Staff Cuts

DateNumber of EmployeesLocationReference
2017-06-2951Article